Terms: = Skin cancer AND ALK, CD246, ENSG00000171094, 238, Q9UM73, TFG/ALK AND Treatment
138 results:
1. Primary cutaneous anaplastic large-cell lymphoma resembling infratemporal space infection: a case report.
Yan X; Ren W; Li S; Zhu Z; Gao L; Zhi K
BMC Oral Health; 2024 Apr; 24(1):470. PubMed ID: 38637781
[TBL] [Abstract] [Full Text] [Related]
2. Detection of TRAF1-alk fusion in skin lesions of systemic alk+ anaplastic large cell lymphoma initially involving the skin and the draining lymph node.
Norimatsu Y; Akatsuka T; Matsuoka A; Hamada T; Mori I; Shiomi T; Mori N; Onishi K; Togashi Y; Inoue N; Takeuchi K; Sugaya M
J Dermatol; 2024 Jan; 51(1):120-124. PubMed ID: 37753577
[TBL] [Abstract] [Full Text] [Related]
3. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
Luo Y; Zhang Z; Guo X; Tang X; Li S; Gong G; Gao S; Zhang Y; Lin S
Lung Cancer; 2023 Oct; 184():107319. PubMed ID: 37597303
[TBL] [Abstract] [Full Text] [Related]
4. Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
Ascierto PA; Di Giacomo AM; Chiarion Sileni V; Queirolo P; Spagnolo F; De Galitiis F; Cognetti F; Mandalà M; Guidoboni M; Rinaldi G; Depenni R; Consoli F; Troiani T; Guida M; Marconcini R; Ferrucci PF; Strippoli S; Fava P; Merelli B; Simeone E; Di Guardo L; Giannarelli D; Maio M; Quaglino P; Del Vecchio M
Eur J Cancer; 2023 Sep; 191():113246. PubMed ID: 37549531
[TBL] [Abstract] [Full Text] [Related]
5. Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.
Aoude LG; Brosda S; Ng J; Lonie JM; Belle CJ; Patel K; Koufariotis LT; Wood S; Atkinson V; Smithers BM; Pearson JV; Waddell N; Barbour AP; Bonazzi VF
J Mol Diagn; 2023 Oct; 25(10):771-781. PubMed ID: 37544359
[TBL] [Abstract] [Full Text] [Related]
6. An update on Alectinib: a first line treatment for alk-positive advanced lung cancer.
Zhou Y; Yin Y; Xu J; Xu Z; Yang B; He Q; Luo P; Yan H; Yang X
Expert Opin Pharmacother; 2023; 24(12):1361-1373. PubMed ID: 37278051
[TBL] [Abstract] [Full Text] [Related]
7. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.
Larkin J; Del Vecchio M; Mandalá M; Gogas H; Arance Fernandez AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Marquez-Rodas I; Butler MO; Di Giacomo AM; Middleton MR; Lutzky J; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill AG; Fecher LA; Millward M; Nathan PD; Khushalani NI; Queirolo P; Ritchings C; Lobo M; Askelson M; Tang H; Dolfi S; Ascierto PA; Weber J
Clin Cancer Res; 2023 Sep; 29(17):3352-3361. PubMed ID: 37058595
[TBL] [Abstract] [Full Text] [Related]
8. Multisystem alk-positive histiocytosis: a multi-case study and literature review.
Liu W; Liu HJ; Wang WY; Tang Y; Zhao S; Zhang WY; Yan JQ; Liu WP
Orphanet J Rare Dis; 2023 Mar; 18(1):53. PubMed ID: 36915094
[TBL] [Abstract] [Full Text] [Related]
9. The Effects of Lack of Awareness in Age-Related Quality of Life, Coping with Stress, and Depression among Patients with Malignant Melanoma.
Toma AO; Boeriu E; Decean L; Bloanca V; Bratosin F; Levai MC; Vasamsetti NG; Alambaram S; Oprisoni AL; Miutescu B; Hemaswini K; Juganaru I; Bondar AC; Moise ML
Curr Oncol; 2023 Jan; 30(2):1516-1528. PubMed ID: 36826077
[TBL] [Abstract] [Full Text] [Related]
10. The safety profile of EGFR/alk-TKIs administered immediately before or after ICIs in advanced NSCLC.
Liao D; Yu L; Chen S; Liu N; Tang J; Yang N
Int Immunopharmacol; 2023 Mar; 116():109787. PubMed ID: 36774856
[TBL] [Abstract] [Full Text] [Related]
11. Mohs micrographic surgery for periocular skin cancer: a single-institution experience.
Shi K; Wang L; Srivastava D; Nijhawan RI
Arch Dermatol Res; 2023 Jul; 315(5):1181-1186. PubMed ID: 36464757
[TBL] [Abstract] [Full Text] [Related]
12. Radiosurgery fractionation and post-treatment hemorrhage development for intact melanoma brain metastases.
McKenzie G; Gaskins J; Rattani A; Oliver A; Southall W; Nakamura F; Yusuf M; Mistry A; Williams B; Woo S
J Neurooncol; 2022 Dec; 160(3):591-599. PubMed ID: 36319794
[TBL] [Abstract] [Full Text] [Related]
13. Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Weber JS; Poretta T; Stwalley BD; Sakkal LA; Du EX; Wang T; Chen Y; Wang Y; Betts KA; Shoushtari AN
Cancer Immunol Immunother; 2023 Apr; 72(4):945-954. PubMed ID: 36197494
[TBL] [Abstract] [Full Text] [Related]
14. Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.
Dankner M; Wang Y; Fazelzad R; Johnson B; Nebhan CA; Dagogo-Jack I; Myall NJ; Richtig G; Bracht JWP; Gerlinger M; Shinozaki E; Yoshino T; Kotani D; Fangusaro JR; Gautschi O; Mazieres J; Sosman JA; Kopetz S; Subbiah V; Davies MA; Groover AL; Sullivan RJ; Flaherty KT; Johnson DB; Benedetti A; Cescon DW; Spreafico A; Zogopoulos G; Rose AAN
JCO Precis Oncol; 2022 Aug; 6():e2200107. PubMed ID: 35977349
[TBL] [Abstract] [Full Text] [Related]
15. State of affairs regarding targeted pharmacological therapy of cancers metastasized to the brain.
Steiger HJ; Vollmer K; Rogers S; Schwyzer L
Neurosurg Rev; 2022 Oct; 45(5):3119-3138. PubMed ID: 35902427
[TBL] [Abstract] [Full Text] [Related]
16. Effectiveness and safety of ultrasound-guided high-intensity focused ultrasound ablation for the treatment of colorectal cancer liver metastases.
Yang T; Chen Q; Kuang L; Fu Z; Wang Y; Chen Y; Yang L; Xu Y
Int J Hyperthermia; 2022; 39(1):829-834. PubMed ID: 35732289
[TBL] [Abstract] [Full Text] [Related]
17. Severe skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung cancer: A Report of Two Cases and a Literature Review.
Nishiyama A; Hattori Y; Takeuchi S; Tanimoto A; Satouchi M; Murayama T; Yano S
Intern Med; 2022 Jun; 61(11):1735-1738. PubMed ID: 34803090
[TBL] [Abstract] [Full Text] [Related]
18. Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation.
Mulder EEAP; Smit L; Grünhagen DJ; Verhoef C; Sleijfer S; van der Veldt AAM; Uyl-de Groot CA
ESMO Open; 2021 Dec; 6(6):100303. PubMed ID: 34781194
[TBL] [Abstract] [Full Text] [Related]
19. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
Weber JS; Ascierto PA; Middleton MR; Hennicken D; Zoffoli R; Pieters A; Amadi A; Kupas K; Kotapati S; Moshyk A; Schadendorf D
Eur J Cancer; 2021 Nov; 158():225-233. PubMed ID: 34663559
[TBL] [Abstract] [Full Text] [Related]
20. "Repeatability of Repeatability": the stability of self-reported melanoma risk factors in two independent samples.
Mortimore A; Pandeya N; Olsen CM; Whiteman DC
Aust N Z J Public Health; 2021 Oct; 45(5):469-473. PubMed ID: 34473389
[TBL] [Abstract] [Full Text] [Related]
[Next]
